Leveraging High Content Phenotypic Screening to Study More Complex and Predictive Disease Models for Drug Discovery
10 Jul 2015
Dr. Eberhard Krausz, from VIB, has the responsibility of translating research findings into drug discovery programs. Advocating the use of cell based screening and assay approaches to drug discovery, Dr. Eberhard discusses in this video how he first began using PerkinElmer’s instruments over ten years ago. Dr. Eberhard recommends PerkinElmer’s latest Opera Phenix High Content Screening System, suggesting it will continue to aid in future studies of complex, predictive disease models to identify new chemicals for drug discovery and development.
Related Products
Request Quote for All Products
EnSight™ Multimode Plate Reader
RevvityThe EnSight ® multimode plate reader offers HTS Alpha and Ultra-sensitive Luminescence technologies alongside conventional multimode detection technologies. When equipped with a quad monochromator, the EnSight plate reader can improve performance for absorbance and fluorescence detection. In addition, stacker and robotic interface options are available, ideal for automation. The system’s modular design, combined with workflow-based Kaleido™ data acquisition and analysis softwar
Opera Phenix High Content Screening System
RevvityThe Opera Phenix ® Plus High-Content Screening System is the premier confocal solution for today' most demanding high content applications. Drawing on over a decade of experience with the industry-leading Opera ® and Opera ® Phenix system, the Opera Phenix Plus is designed for high-throughput high-content assays, phenotypic screening, assays using complex disease models, such as live cells, primary cells and microtissues, and fast-response assays, such as Ca2+ flux.